Joseph Harlan is an Ophthalmologist in Lutherville, Maryland. Dr. Harlan is rated as a Distinguished provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Retinal Artery Occlusion, and Age-Related Macular Degeneration (ARMD). Dr. Harlan is currently accepting new patients.

Mandeep S. Singh, M.D., Ph.D., is associate professor of ophthalmology and genetic medicine in the Retina Division of the Wilmer Eye Institute and the recipient of the 2023 Andreas C. Dracopoulos Professorship in Ophthalmology. Dr. Singh is a retinal specialist. He is Co-Director of the Genetic Eye Disease (GEDi) Center, and is a principal investigator at the Center for Stem Cells and Ocular Regenerative Medicine (STORM). Dr. Singh completed his medical degree at the National University of Singapore. In 2009, he was elected to the Fellow of the Royal College of Surgeons of Edinburgh. He earned a PhD in ophthalmology from the University of Oxford, United Kingdom, in 2014. He completed fellowships in vitreoretinal diseases and surgery at the Oxford Eye Hospital and Moorfields Eye Hospital, both in the United Kingdom. His clinical expertise includes surgical, medical and genetic conditions of the retina and macula. Dr. Singh is specialty-trained in vitrectomy surgery for retinal detachment, macular holes, macular pucker, epiretinal membrane, proliferative vitreoretinopathy, complex retinal detachments including reoperations, vitreous hemorrhage removal, and other retinal surgeries. He also specializes in age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization. Dr. Singh sees patients and families with genetic retinal diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease and macular dystrophies. His research focus is retinal stem cell transplantation. Dr. Singh’s work has been recognized through the Eye Institute–Allergan Research Prize, the Merton College University of Oxford Graduate Prize Scholarship, the Oxford Ophthalmological Congress Founder’s Cup and Medal, the Ruskell Medal, the Johns Hopkins Clinician Scientist Award, and the Bert M. Glaser, MD Award for Innovative Research in Retina. He is a member of the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. He is also a member of the Club Jules Gonin and the Macula Society. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Singh_CV.pdf. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Leber Congenital Amaurosis, Sorsby Fundus Dystrophy, Usher Syndrome Type 2A, and Doyne Honeycomb Retinal Dystrophy.

Janet Sunness is an Ophthalmologist in Baltimore, Maryland. Dr. Sunness is rated as a Distinguished provider by MediFind in the treatment of Usher Syndrome Type 2A. Her top areas of expertise are Stargardt Macular Degeneration, Geographic Atrophy, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration (ARMD). Dr. Sunness is currently accepting new patients.

Marcos Doxanas is an Ophthalmologist and a Plastic Surgeon in Annapolis, Maryland. Dr. Doxanas is rated as a Distinguished provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Dry Eye Syndrome, Chalazion, Eyelid Bump, and Cataract. Dr. Doxanas is currently accepting new patients.

Yannis M. Paulus, M.D., F.A.C.S., is the Jonas Fridenwald Professor in Ophthalmology, an associate professor in the Johns Hopkins University Department of Ophthalmology and Department of Biomedical Engineering, and a vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Medicine’s East Baltimore and Columbia locations. Dr. Paulus served as a surgical retina specialist and director of a research laboratory at the University of Michigan Kellogg Eye Center for almost 10 years, where he developed novel imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs. After earning his bachelor’s degree in chemistry and physics from Harvard University and his medical degree at Stanford University School of Medicine, Dr. Paulus completed an internship at the Sloan-Kettering Cancer Center, a residency in ophthalmology at the Stanford University School of Medicine Byers Eye Institute, and a surgical and medical retina fellowship at Wilmer Eye Institute, Johns Hopkins Medicine. CVhttps://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Paulus_CV%2021225.pdf. Dr. Paulus is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

Dr. Susan Bressler is the Julia G. Levy, Ph.D. Professor of Ophthalmology at the Wilmer Eye Institute. She is an ophthalmologist and has subspecialty training in medical retinal disorders, vitreoretinal disease, and retinal surgery. Her main research interest has been collaborative efforts in clinical trials - serving as principal investigator of an image reading center that has served as a central unit for many clinical trials and epidemiologic investigations, as Vice Chair of the Diabetic Retinopathy Clinical Research Network and as principal investigator of a participating clinical center in several major clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular age-related macular degeneration and all aspects of diabetic retinopathy. Dr. Bressler has a large national and international referral practice. In addition, she has published 223 peer reviewed articles and 55 book chapters. Editorial Board positions have included American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, Health After 50: The Johns Hopkins Medical Letter and the Wilmer Retina Update. Dr. Bressler is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. Her top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Vitrectomy.

Adam Gerstenblith is an Ophthalmologist in Hagerstown, Maryland. Dr. Gerstenblith is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Diabetic Retinopathy, and Vitrectomy. Dr. Gerstenblith is currently accepting new patients.

Michael Grodin is an Ophthalmologist in Lutherville, Maryland. Dr. Grodin is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Retinal Artery Occlusion. Dr. Grodin is currently accepting new patients.

Ingrid Zimmer-Galler is an Ophthalmologist in Frederick, Maryland. Dr. Zimmer-Galler is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. Her top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), and Diabetic Retinopathy. Dr. Zimmer-Galler is currently accepting new patients.

T. Y. Alvin Liu, M.D. is the James P. Gills, Jr. M.D., and Heather Gills Rising Professor of AI and the founding director of the Wilmer Precision Ophthalmology Center of Excellence. He is originally from Hong Kong, and speaks fluent Cantonese and Mandarin. He attended Phillips Exeter Academy in Exeter, New Hampshire, and graduated from Cornell University with a dual major in biology and economics. He received his M.D. from Columbia University in 2012, and completed his residency (2016) and fellowship (surgical and medical retina- 2018) at Johns Hopkins. He is subspecialty-trained in the medical and surgical treatment of vitreoretinal diseases, including age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vascular occlusion, retinal detachment, vitreous hemorrhage, epiretinal membrane and macular hole. Dr. Liu's research interests center on the application of artificial intelligence in the screening, diagnosis, prognostication and treatment of ophthalmic diseases, with a specific focus on vitreoretinal diseases such as age-related macular degeneration and diabetic retinopathy. In addition, he is involved in research on the pathogenesis of and treatment for pathologic myopia and the management of severe ocular trauma. Videos Dr. Tin Yan Alvin Liu Recent News Articles and Media Coverage AI Speeds Diabetic Retinopathy Diagnosis Without Specialist. Medscape August 28, 2018 AI Screening for Diabetic Retinopathy Moves to Retail Clinics. Medscape November 26, 2019 How Artificial Intelligence is Primed to Change Ophthalmology. Ophthalmology Advisor May 14, 2021 Medicine's first autonomous AI could prevent blindness due to diabetes. Stat News December 16, 2021 Innovations in Eye Care: How Technology is Transforming Ophthalmology. HealthTech November 29, 2022 Time to go multicultural. Retina Today March 1, 2023 How deep learning may play a role in predicting retinitis pigmentosa visual impairment. Ophthalmology Times March 14, 2023 AI in retinal diagnostics. Zhaoke Ophthalmology March 22, 2023 Macular Degeneration. Spotlight on Geographic Atrophy. Advances in Treatment. WebMD April 23, 2023 ARVO 2023: T.Y. Alvin Liu, MD discusses predictive AI and its application in ophthalmology. Modern Retina April 25, 2023 ASCRS: Prediction of imminent conversion to neovascular AMD using deep learning and 3D OCT volumes. OptometryTimes May 5, 2023 Adopting and regulating AI in healthcare. BNN Bloomberg May 29, 2023 AI could increase health equity and boost adherence to annual eye examination in patients with diabetes. Modern Retina June 21, 2023 As more Marylanders grow older, a debilitating eye disease is gaining ground. The Baltimore Banner June 26, 2023. Dr. Liu is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Usher Syndrome Type 2A, Cone Rod Dystrophy Amelogenesis Imperfecta, Cone-Rod Dystrophy, and Stargardt Macular Degeneration.

Jesus Martinez is an Ophthalmologist in Rockville, Maryland. Dr. Martinez is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Pterygium, Glaucoma, Dry Eye Syndrome, and Cataract. Dr. Martinez is currently accepting new patients.

Fritz Allen is an Ophthalmologist in Rockville, Maryland. Dr. Allen is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Glaucoma, Retinal Vasculopathy with Cerebral Leukodystrophy, Familial Exudative Vitreoretinopathy, and Coats Disease. Dr. Allen is currently accepting new patients.

Saman Ghahremani is an Ophthalmologist in Silver Spring, Maryland. Dr. Ghahremani is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Dry Eye Syndrome, Ocular Hypertension (OHT), Glaucoma, and Pinguecula. Dr. Ghahremani is currently accepting new patients.

Adam Wenick is an Ophthalmologist in Hagerstown, Maryland. Dr. Wenick is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Vein Occlusion, Retinal Detachment, and Vitrectomy. Dr. Wenick is currently accepting new patients.

Elia J. Duh, M.D., is the G. Edward and G. Britton Durell Professor of Ophthalmology at the Wilmer Eye Institute. He has a joint appointment in the Department of Chemical and Biomolecular Engineering, The Whiting School of Engineering. He specializes in diseases of the retina, including diabetic retinopathy and age-related macular degeneration. In addition to his clinical practice, Dr. Duh actively researches the molecular mechanisms underlying diabetic retinopathy and macular degeneration, particularly the process of ocular neovascularization and excessive retinal vascular permeability. His research has helped determine the role of the major antioxidant regulator, Nrf2, in retinal diseases, and also connected Nrf2 to lifespan. His work has also provided insights into the involvement of the eye in COVID-19. Dr. Duh’s interest in developing new treatments for retinal diseases includes nanomedicine approaches for targeted drug delivery to the eye. Dr. Duh graduated summa cum laude from Yale University and obtained his medical degree from Harvard Medical School. He completed his ophthalmology residency and medical retina fellowship at the Wilmer Eye Institute. He was elected to the American Society of Clinical Investigation in 2016. Dr. Duh is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Vein Occlusion, and Vitrectomy.

Akrit Sodhi, M.D, Ph.D., is an Associate Professor of Ophthalmology at the Wilmer Eye Institute and holds the Branna and Irving Sisenwein Professorship in Ophthalmology. Dr. Sodhi specializes in the medical and surgical management of complex vitreoretinal diseases. Dr. Sodhi was trained at the University of California at Los Angeles (UCLA), the University of California at Davis, and the National Institutes of Health. After obtaining his M.D. and Ph.D., he interned at Sinai Hospital in Baltimore and completed his Ophthalmology Residency training at the Wilmer Eye Institute at Johns Hopkins in 2008. He then pursued a fellowship in vitreoretinal surgery at Wilmer where he also served as the Assistant Chief of Service (Chief Resident). Dr. Sodhi joined the faculty of the Retina Division at Wilmer in 2010. His research interests, currently sponsored by grants from the National Eye Institute, include the examination of the role of hypoxia inducible factor (HIF) and HIF-regulated genes in ocular diseases, including diabetic eye disease, age-related macular degeneration, sickle cell retinopathy, retinal vein occlusions, and uveal melanoma. Dr. Sodhi's lab has identified novel therapeutic targets for the treatment of these vision-threatening diseases. Dr. Sodhi is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Late-Onset Retinal Degeneration.

Gayatri Reilly is an Ophthalmologist in Chevy Chase, Maryland. Dr. Reilly is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. Her top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Neuroretinitis, Retinal Detachment, and Vitrectomy. Dr. Reilly is currently accepting new patients.

Zaaira Ahmad is an Ophthalmologist in Salisbury, Maryland. Dr. Ahmad is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. Her top areas of expertise are Endophthalmitis, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Ahmad is currently accepting new patients.

Chetankumar Patel is an Ophthalmologist in Rockville, Maryland. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Endophthalmitis. Dr. Patel is currently accepting new patients.

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Advanced provider by MediFind in the treatment of Usher Syndrome Type 2A. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.